

Media Outlet: Biospace

Date: 11th September

URL: <http://www.biospace.com/News/data-shows-ma-activity-increases-44-5-in-india/391038>

The screenshot shows the Biospace website interface. At the top left is the Biospace logo with the tagline 'Life Sciences News + Jobs'. To the right are logos for 'VERTEX THE SCIENCE OF POSSIBILITY' and 'BEST PLACES TO WORK'. A navigation menu includes links for HOME, NEWS, JOBS, CAREER RESOURCES, HOTBEDS, CAREER FAIRS, EVENTS, COMPANY PROFILES, and INVEST. Below the menu is a search bar for 'Search Life Sciences Jobs' with input fields for 'Job Title, Keyword or Company Name' and 'City, State, or Postal Code', and a 'FIND' button. A secondary navigation bar offers links for 'News | News By Subject | News by Disease | News By Date | Search News'. A newsletter sign-up box prompts users to 'Get Our FREE Industry eNewsletter' with an email input field and a 'Sign Up Now' button. Below this are 'EMAIL' and 'PRINT' icons. The main article title is 'Data Shows M&A Activity Increases 44.5% In India', followed by social media sharing buttons for Facebook (Like, Share), Twitter (Tweet), LinkedIn (Share), and Google+ (G+). The article timestamp is '9/11/2015 8:07:57 AM'. The text of the article begins with 'Exports and domestic market valued at over \$15 billion each, with India expected to take 25% of biosimilars market over the next five years'. A sub-headline reads 'New Delhi, September 10, 2015 IBEF (India Brand Equity Foundation): The Indian domestic pharma market is estimated at INR 90,400 crore (US\$ 15 bn) ending FY15 with a growth of 12%. It is estimated that almost 27-30% of India's pharmaceutical'.

Data Shows M&A Activity Increases 44.5% In India

9/11/2015 8:07:57 AM

Exports and domestic market valued at over \$15 billion each, with India expected to take 25% of biosimilars market over the next five years

New Delhi, September 10, 2015 IBEF (India Brand Equity Foundation): The Indian domestic pharma market is estimated at INR 90,400 crore (US\$ 15 bn) ending FY15 with a growth of 12%. It is estimated that almost 27-30% of India's pharmaceutical market is catered to by multinationals operating in India and around 4,60,000 people are estimated to be employed in

the pharmaceutical industry. Top 20 companies account for 64% of the market. 8 out of the top 20 are growing faster than the market, with Macleoids topping the list with 23.4% growth followed by Intas with 21.3%, Cipla 19.7% Glenmark over 19.4% growth and Mankind 19.3%. Besides, India's pharma exports stood at US\$ 15.3 billion in 2014-15. There were M&A activities in the industry accounted for \$ 5.78, billion an increase of around 44.5% in comparison to 2013.

The Government's continuous and concerted efforts have resulted in the reach of modern medicine to almost all corners of the country, and its measures have resulted in the steady decline of communicable diseases. The successful eradication of Polio, Small Pox etc. can be attributed entirely to the tireless efforts of the Government. The Ministry of Health and Family Welfare is responsible for the implementation of national health and family welfare programmes such as the prevention and control of major communicable diseases, maternal and child health.

Public-private partnerships, an increased penetration of healthcare facilities in non-metro cities, involvement of multinationals in setting up facilities in the country, and establishment of educational institutions, are just a few multiple prime reasons enabling India to experience a surge in the global market. Other key assets which have played a role in India becoming a leading pharma market are a thorough know-how in the manufacture of generics, rapidly developing research and development facilities with talented technical staffing, internationally recognised systems of pharmacy education, and a broad patient population pool enabling intense clinical trials.

India accounts for 30.3% (2,911) of 9619 Drug Master Files (DMFs) filed with the USA, which is the highest outside of the USA. India has been accredited with approximately 1187 CEPs, more than 950TGA, and 584 sites approved by USFDA. Despite a challenging intellectual property regime, pharmaceutical R&D activities are increasing in India. An

average of 8-10% of the total revenue of the India domestic pharma market, i.e. US\$ 15 billion, is spent on R&D. ZydusCadilla has launched "Lipaglyn" (Chemical name is Saroglitazar), its original research being to treat Hypertriglycerdemia in Type-2 diabetes. Glenmark has several new chemical and biologics. Contract Research and Manufacturing Services (CRAMS) in India is estimated to reach US\$ 18 billion in 2018, up from US\$ 7.6–7.8 billion in 2013. The biopharma market is valued at US\$ 2.5 billion whereas India is expected to grab at least 20-25% of global market share in biosimilars in the next five years.

India is also making inroads to new regulated markets like Japan. Several initiatives have been undertaken by industry for engaging with Japanese pharma companies, including contract manufacturing of advance intermediates for drugs under clinical development/about to be made commercial, marketing APIs to Japanese Generic and Innovation companies, providing quality intermediates to the Japanese innovator companies.

In summary, the last few years have reshaped and repositioned India in the realm of healthcare and pharmaceuticals, and the results have started to show in its high ranking position in the global pharmaceutical market.

About IBEF

India Brand Equity Foundation (IBEF) is a Trust established by the Department of Commerce, Ministry of Commerce and Industry, Government of India. IBEF's primary objective is to promote and create international awareness of the Made in India label in markets overseas and to facilitate dissemination of knowledge of Indian products and services. Towards this objective, IBEF works closely with stakeholders across government and industry.